Shilpa Medicare: Business Overview & Financial Analysis
Shilpa Medicare is a research-driven Indian pharmaceutical manufacturing enterprise headquartered in Raichur, Karnataka. Promoted by Omprakash Inani and Vishnukant Bhurada, the company operates across active pharmaceutical ingredients (APIs), finished dosage formulations (FDF), oncology therapeutics, complex biologics, and specialized polymers. Managing advanced chemical synthesis and sterile formulation plants in Karnataka, Andhra Pradesh, and Telangana, Shilpa Medicare supplies niche oncology APIs, oral solids, liquid injectables, transdermal patches, and oral thin films to generic drug majors and health systems across North America, Europe, Japan, and domestic Indian markets.
Business Segment Revenue Breakdown of Shilpa Medicare (FY2026)
Shilpa Medicare structures its operational turnover across active pharmaceutical ingredients (APIs), finished dosage formulations (FDF), biologics, and polymers.
- Active Pharmaceutical Ingredients (API) Division – 54.2% of Total Operating Revenue
- Finished Dosage Formulations (FDF) Division – 38.5% of Total Operating Revenue
- Biologics & Specialty Polymers Division – 7.3% of Total Operating Revenue
- Total Consolidated Revenue from Operations (FY2026) – Rs 1,549.00 crore (+18.0% YoY)
Active pharmaceutical ingredients (APIs) represent the core revenue anchor, led by high-margin oncology and non-oncology synthetic molecules. The finished dosage formulation (FDF) division delivers finished oral solids and sterile injectables, while biologics and specialized polymers expand high-barrier technology realisations.
Therapeutic Portfolio & Product Mix of Shilpa Medicare (FY2026)
Shilpa Medicare focuses on high-complexity, high-barrier therapeutic verticals including oncology, peptides, and transdermal delivery systems.
- Oncology Therapeutics Share – 52.0% of Total Group Revenue
- Non-Oncology & Chronic Care Share – 40.5% of Total Group Revenue
- Peptides, Biologics & Specialty Formulations – 7.5% of Total Group Revenue
- Total Commercialised API Molecules Portfolio – 45+ active commercial oncology and non-oncology APIs
Oncology APIs and formulations constitute over half of consolidated turnover, positioning the enterprise among India's leading oncology ingredient suppliers. Peptides and transdermal film formulations provide next-generation growth catalysts.
Geographic Revenue Mix & Export Footprint of Shilpa Medicare (FY2026)
Shilpa Medicare generates over six-tenths of its operational turnover through direct drug exports to regulated global healthcare markets.
- Europe & United Kingdom Share – 32.5% of Total Operating Revenue
- North America (USA & Canada) Share – 22.8% of Total Operating Revenue
- India Domestic Market Share – 34.2% of Total Operating Revenue
- Rest of the World (RoW) & LATAM Share – 10.5% of Total Operating Revenue
- Regulated Markets Contribution Share – ~65.0% of Total Operating Revenue
Regulated markets in Europe and North America contribute nearly two-thirds of total revenues, supported by direct generic partnerships. Domestic sales supply leading Indian formulation exporters and institutional oncology hospital networks.
Global Manufacturing Infrastructure & USFDA Approvals of Shilpa Medicare (FY2026)
Shilpa Medicare operates specialized synthesis and formulation complexes certified by global health authorities.
- Operational Manufacturing Facilities Base – 6 specialized manufacturing units in India
- API Manufacturing Sites – Raichur (Karnataka - Oncology & Non-Oncology API complexes)
- Formulation Plants Locations – Jadcherla (Telangana - Injectables & Oral Solids) and Bengaluru (Karnataka)
- Biologics & Polymers Facilities – Dharwad (Karnataka) and Hyderabad (Telangana)
- Regulatory Approvals Status – USFDA, EU-GMP, PMDA (Japan), and WHO-GMP accredited facilities
- USFDA Audit Status – Bengaluru facility received Voluntary Action Indicated (VAI) classification from USFDA
The Bengaluru formulation unit holds USFDA VAI classification, facilitating product dispatches to North America. Large-scale fermentation and chemical synthesis reactors in Raichur supply complex active ingredients under stringent global compliance standards.
Latest Quarterly Financial Performance of Shilpa Medicare (Q4 FY2026 / Q1 FY2027)
Shilpa Medicare achieved record quarterly top-line revenue expansion and net profit growth.
- Consolidated Revenue from Operations (Q4 FY2026) – Rs 439.00 crore (+30.0% YoY)
- Quarterly Consolidated Net Profit After Tax (PAT - Q3 FY2026) – Rs 42.00 crore
- Quarterly Operating EBITDA Margin (Q3 FY2026) – 8.70%
- Gross Profit Margin Profile – 52.80%
Fourth-quarter operating revenue rose 30% year-on-year to a historic high of Rs 439.00 crore. Third-quarter Net Profit After Tax reached Rs 42.00 crore, supported by volume acceleration in oncology API exports.
Consolidated Annual Financial Performance of Shilpa Medicare (FY2026)
Shilpa Medicare delivered historic high full-year turnover expansion and operating profit growth for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 1,549.00 crore (+18.0% YoY)
- Full Year Consolidated Operating EBITDA – Rs 312.50 crore (+22.4% YoY)
- Full Year Operating EBITDA Margin – 20.17% (+72 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 145.20 crore (+28.5% YoY)
- Return on Capital Employed (ROCE) – 14.8%
Full-year operating turnover crossed Rs 1,540 crore in FY2026, driven by an 18% top-line revenue expansion. Operating EBITDA demonstrated robust growth, supported by oncology API order book conversion and capacity utilization gains.
Balance Sheet Structure & Financial Health Ratios of Shilpa Medicare (FY2026)
Shilpa Medicare operates a balanced capital structure backed by operational cash flow conversion and long-term credit discipline.
- Consolidated Debt to Equity Ratio – 0.38x
- Total Cash, Bank Balances & Surplus Investments – Rs 285.00 crore
- Total Consolidated Net Worth Base – Rs 2,150.00 crore
- Return on Equity (ROE) – 11.5%
- Working Capital Cycle – 112 days
Total net worth expanded to Rs 2,150.00 crore as of March 31, 2026, with debt to equity holding comfortable at 0.38x. The ongoing RBI rate cut cycle in 2026 helps compress borrowing costs and improves EBITDA-to-PAT conversion.
Capital Expenditure & Biologics Pipeline Roadmap of Shilpa Medicare (FY2027–FY2028)
Shilpa Medicare executes capital allocation outlays to scale transdermal patch manufacturing and expand biologics processing capacity.
- Total Planned Multi-Year Capex Outlay – Rs 250–300 crore over FY2027–FY2028
- Transdermal & Oral Film Expansion – Scaling automated transdermal patch lines at Hyderabad
- Dharwad Biologics Unit Outlay – Adding recombinant protein and biosimilar production suites
- R&D & Regulatory Filings Outlay – Annual R&D budget allocated at 6.0%–8.0% of total revenue
- Funding Method – Funded through internal operational cash accruals and debt facilities
Capital expenditure is budgeted to expand transdermal patch lines in Hyderabad and scale biosimilar suites in Dharwad. R&D outlays totaling 6%–8% of annual revenue support complex peptide and biosimilar ANDA filings.
Strategic Outlook & Management Commentary of Shilpa Medicare (FY2026 / FY2027)
Management guidance outlines strategic priorities centered on oncology market share preservation, transdermal commercialization, and biologics scaling.
- Management targets achieving a 15%–20% top-line revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain within the 20.0%–22.0% corridor through high-margin oncology execution.
- Transdermal films and oral thin patches will be commercialized across European and North American retail channels.
- Biologics and biosimilar portfolio contribution is targeted to reach 10%–12% of total turnover over 3 years.
- Capital allocation strategy will prioritize keeping debt to equity below 0.50x while funding greenfield R&D projects.
Management projects strong financial momentum following record full-year revenues in FY2026. Operational focus centers on converting the existing oncology order book, scaling transdermal dispatches, and maintaining balance sheet discipline.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Shilpa Medicare Limited Q4 FY2026 & Full Year FY2026 Audited Financial Disclosures (May 2026)
- Shilpa Medicare Limited Q3 FY2026 Unaudited Financial Disclosures (February 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Shilpa Medicare Limited
- Ticker Finology Shilpa Medicare Page
Disclaimer
The information presented above on Shilpa Medicare has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Shilpa Medicare page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.